Genentech, Biogen ask FDA to broaden Rituxan use

Genentech and partner Biogen Idec are asking the FDA to allow their cancer drug Rituxan to be used in combination with chemotherapy for people with chronic lymphocytic leukemia. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.